CONSTANCE WANTLING: Open Payments
NPI 1528110137 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$384 in 19 payments from 8 companies in 2025. Trend: 2023 $82 · 2024 $285 · 2025 $384
Food & beverage: $365Education: $19
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $83 |
| AstraZeneca Pharmaceuticals LP | 4 | $78 |
| Novo Nordisk Inc | 3 | $71 |
| Astellas Pharma US Inc | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
| GlaxoSmithKline, LLC. | 1 | $32 |
| Exact Sciences Corporation | 1 | $20 |
| PFIZER INC. | 1 | $18 |
Products named: MOUNJARO, FARXIGA, Ozempic, Veozah, JARDIANCE, TRELEGY ELLIPTA, Cologuard Collection Kit, BREZTRI.
Industry payments across MD — which companies pay providers there.
